Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Libi Pharm Ltd. holds a company patent portfolio situated in the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action, indicating a focused stage of legal review. This single action is localized within 1 distinct art unit, suggesting that the company's current intellectual property strategy is targeted toward a specific regulatory or technical category. For practitioners, this means the prosecution is subject to the specialized examination practices of a single technical division within the patent office.
Prosecution is overseen by 1 distinct examiner, PAK, JOHN D. This individual is identified as the busiest examiner for the portfolio, with 1 busiest examiner pending action currently on their docket. Since there is only 1 pending office action in total, PAK, JOHN D manages the entire active workload for the company. This 1 to 1 ratio between total pending actions and those assigned to the busiest examiner shows that all current legal hurdles for the company are consolidated under a single individual's review. This concentration means that the outcome of the company's current filings is entirely subject to the review and requirements of this 1 examiner within the designated 1 art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PAK, JOHN D | 1 | 52.4% | +37.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280930 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING A DISEASE OR A CONDITION | PAK, JOHN D | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18280930 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING A DISEASE OR A CONDITION | PAK, JOHN D | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18280930 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING A DISEASE OR A CONDITION | PAK, JOHN D | 1624 | §102§103§112 | Non-Final OA | — | Pending | Sep 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial